NCT03969303View on ClinicalTrials.gov

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

CompletedOBSERVATIONAL

Enrollment

287

Participants

Timeline

Start Date

October 20, 2018

Primary Completion Date

July 11, 2019

Study Completion Date

October 4, 2019

Conditions

AMD - Age-Related Macular DegenerationDiabetic Macular Edema

Interventions

DEVICE

Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)

OCT SCAN

Trial Locations (1)

21237

Elman Retina Group, PA, Baltimore

Sponsors

Lead Sponsor

Notal Vision Ltd.

All Listed Sponsors

collaborator

Elman Retina Group

OTHER

lead

Notal Vision Ltd.

INDUSTRY

NCT03969303 - NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients | Biotech Hunter | Biotech Hunter